Update on Pharmacotherapy for Pulmonary Hypertension


Pulmonary arterial hypertension (PAH) is a rare disease with a poor prognosis if not treated. Pharmacological treatment options for PAH have increased significantly over the past 10 years, with availability of intravenous, oral and inhaled drugs targeting the nitric oxide, endothelin and prostacyclin pathways.

This module includes an evidence-based overview of PAH treatment as applied to clinical practice, focusing on Group 1 and Group 4 PH (for which there is good evidence for pharmacological treatment).


Learning Outcomes

  1. Recognise that PAH is a rare disease with a poor prognosis if not treated
  2. Become familiar with several new oral drugs beneficial in treating PAH, impacting future treatments


Authors: David L Prior, Heath Adams, Trevor J Williams

Article Type: Narrative review


Medical Journal of Australia
Reading: journal; textbook; book; literature review
1h : 0m
MBA: 1h : 0m
Cardiovascular Diseases
Medical Practitioner, Medical Student, Doctor-in-Training, Non-Vocationally Registered, Nurse / Midwife, Pharmacist, Podiatrist, Researcher, Retired, Specialist - Other, Specialist General Practitioner
You have to be logged in to see the content of this module.

Provided by

doctorportal Learning respectfully acknowledges Aboriginal and Torres Strait Islander peoples as the first inhabitants of Australia. We respect the traditional owners of lands across Australia in which our members and staff work and live, and pay respect to their elders past, present and emerging.